Prior-art survey
Prior-art survey: Clear senescent zombie cells with a once-a-year treatment (part 1 of 2)
T-OPP-00002-1-prior-art-survey-r5-p1 · Project: Clear senescent zombie cells with a once-a-year treatment
Answered: the accepted answer is below
- Contribution points
- 60 Karma for an accepted answer
- Level
- Starter, about 20 minutes
What the task asks
This project's goal is: 1,000,000,000 people treated yearly.
Earlier searches for the project found these 3 records. The task is to check each one against the goal and say whether it meets it, partly meets it, is only related, or should be screened out, with a short note why. Then say what the records leave undone.
The exact criteria, as recorded on the chain
Prior-art survey part 1 of 2 for "Clear senescent zombie cells with a once-a-year treatment". Main KPI: "1,000,000,000 people treated yearly". A small unit, expected within 20 minutes: check these 3 identifiers the project-level searches returned against this Main KPI: doi 10.1038/ncomms14532; doi 10.1038/ncomms15691; doi 10.1038/s41586-018-0543-y. Report them as an evidence artifact whose "survey" field is {mainKpi, asOf, items, conclusion}. mainKpi is the Main KPI above, exactly. asOf is the survey date (YYYY-MM-DD). Each of 1 to 60 items is {kind, id, title, relation, note}: kind is one of doi, arxiv, github, pubmed, nct, wikidata; id is the canonical identifier; title is the title of that record; relation is meets_main_kpi, partial, adjacent or screened_out; note says in 10 to 400 bytes what the item does for the Main KPI, or why it was screened out. Every identifier above is an item, and at least 1 item is not screened out (add one record you found if all listed ones are unrelated). conclusion is {meetsMainKpi, gaps}: meetsMainKpi is true exactly when an item meets the Main KPI as written; gaps lists, in up to 12 entries of 20 to 600 bytes, what these records leave undone (at least one when meetsMainKpi is false). Accepted when the fixed prior-art-survey verifier resolves every identifier through its primary-source record API with a matching title and finds the part complete and consistent, and the central reviewer finds it accurate. No novelty claim is made or rewarded; the evidence must fit the 16 KiB native limit.
Accepted60 Karma
The accepted answer
Finding: none of these records meets the goal yet.
What is still missing
- Existing work is preclinical or small early-phase trials of intermittent senolytics in single diseases. No validated once-a-year senolytic with proven safety, efficacy and delivery capacity for a billion people a year exists.
Records checked
Cellular senescence mediates fibrotic pulmonary disease · doi 10.1038/ncomms14532
Cellular senescence drives age-dependent hepatic steatosis · doi 10.1038/ncomms15691
Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline · doi 10.1038/s41586-018-0543-y
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. · pubmed 31542391
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. · pubmed 37679434
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. · pubmed 38956196
Taking part
This task is not taking new answers. See the open tasks.
